Areej Abuhammad, Mutasem Taha. Future Med Chem 2016
Times Cited: 11
Times Cited: 11
Times Cited
Times Co-cited
Similarity
Interpreting steep dose-response curves in early inhibitor discovery.
Brian K Shoichet. J Med Chem 2006
Brian K Shoichet. J Med Chem 2006
100
Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4.
Nicolas Triballeau, Francine Acher, Isabelle Brabet, Jean-Philippe Pin, Hugues-Olivier Bertrand. J Med Chem 2005
Nicolas Triballeau, Francine Acher, Isabelle Brabet, Jean-Philippe Pin, Hugues-Olivier Bertrand. J Med Chem 2005
100
Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection--what can we learn from earlier mistakes?
Johannes Kirchmair, Patrick Markt, Simona Distinto, Gerhard Wolber, Thierry Langer. J Comput Aided Mol Des 2008
Johannes Kirchmair, Patrick Markt, Simona Distinto, Gerhard Wolber, Thierry Langer. J Comput Aided Mol Des 2008
81
Elaborate ligand-based modeling coupled with QSAR analysis and in silico screening reveal new potent acetylcholinesterase inhibitors.
Sawsan Abuhamdah, Maha Habash, Mutasem O Taha. J Comput Aided Mol Des 2013
Sawsan Abuhamdah, Maha Habash, Mutasem O Taha. J Comput Aided Mol Des 2013
72
Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of new potent hormone sensitive lipase inhibitors.
Mutasem O Taha, Lina A Dahabiyeh, Yasser Bustanji, Hiba Zalloum, Suhair Saleh. J Med Chem 2008
Mutasem O Taha, Lina A Dahabiyeh, Yasser Bustanji, Hiba Zalloum, Suhair Saleh. J Med Chem 2008
72
Docking-based comparative intermolecular contacts analysis as new 3-D QSAR concept for validating docking studies and in silico screening: NMT and GP inhibitors as case studies.
Mutasem O Taha, Maha Habash, Zeina Al-Hadidi, Amal Al-Bakri, Khaled Younis, Suhaib Sisan. J Chem Inf Model 2011
Mutasem O Taha, Maha Habash, Zeina Al-Hadidi, Amal Al-Bakri, Khaled Younis, Suhaib Sisan. J Chem Inf Model 2011
72
Designing screens: how to make your hits a hit.
W Patrick Walters, Mark Namchuk. Nat Rev Drug Discov 2003
W Patrick Walters, Mark Namchuk. Nat Rev Drug Discov 2003
72
The use of docking-based comparative intermolecular contacts analysis to identify optimal docking conditions within glucokinase and to discover of new GK activators.
Mutasem O Taha, Maha Habash, Mohammad A Khanfar. J Comput Aided Mol Des 2014
Mutasem O Taha, Maha Habash, Mohammad A Khanfar. J Comput Aided Mol Des 2014
72
Discovery of new antifungal leads via pharmacophore modeling and QSAR analysis of fungal N-myristoyl transferase inhibitors followed by in silico screening.
Mutasem O Taha, Amjad M Qandil, Tariq Al-Haraznah, Reema Abu Khalaf, Hiba Zalloum, Amal G Al-Bakri. Chem Biol Drug Des 2011
Mutasem O Taha, Amjad M Qandil, Tariq Al-Haraznah, Reema Abu Khalaf, Hiba Zalloum, Amal G Al-Bakri. Chem Biol Drug Des 2011
63
Validation studies of the site-directed docking program LibDock.
Shashidhar N Rao, Martha S Head, Amit Kulkarni, Judith M LaLonde. J Chem Inf Model 2007
Shashidhar N Rao, Martha S Head, Amit Kulkarni, Judith M LaLonde. J Chem Inf Model 2007
63
Application of docking-based comparative intermolecular contacts analysis to validate Hsp90α docking studies and subsequent in silico screening for inhibitors.
Mahmoud A Al-Sha'er, Mutasem O Taha. J Mol Model 2012
Mahmoud A Al-Sha'er, Mutasem O Taha. J Mol Model 2012
63
Pharmacophore modeling and three-dimensional database searching for drug design using catalyst.
Y Kurogi, O F Güner. Curr Med Chem 2001
Y Kurogi, O F Güner. Curr Med Chem 2001
63
Discovery of novel urokinase plasminogen activator (uPA) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.
Mahmoud A Al-Sha'er, Mohammad A Khanfar, Mutasem O Taha. J Mol Model 2014
Mahmoud A Al-Sha'er, Mohammad A Khanfar, Mutasem O Taha. J Mol Model 2014
63
Elaborate ligand-based modeling reveal new migration inhibitory factor inhibitors.
Mahmoud A Al-Sha'er, Sonya VanPatten, Yousef Al-Abed, Mutasem O Taha. J Mol Graph Model 2013
Mahmoud A Al-Sha'er, Sonya VanPatten, Yousef Al-Abed, Mutasem O Taha. J Mol Graph Model 2013
63
LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites.
C M Venkatachalam, X Jiang, T Oldfield, M Waldman. J Mol Graph Model 2003
C M Venkatachalam, X Jiang, T Oldfield, M Waldman. J Mol Graph Model 2003
54
A general and fast scoring function for protein-ligand interactions: a simplified potential approach.
I Muegge, Y C Martin. J Med Chem 1999
I Muegge, Y C Martin. J Med Chem 1999
54
Elaborate ligand-based modeling reveals new nanomolar heat shock protein 90α inhibitors.
Mahmoud A Al-Sha'er, Mutasem O Taha. J Chem Inf Model 2010
Mahmoud A Al-Sha'er, Mutasem O Taha. J Chem Inf Model 2010
54
Combining docking-based comparative intermolecular contacts analysis and k-nearest neighbor correlation for the discovery of new check point kinase 1 inhibitors.
Nour Jamal Jaradat, Mohammad A Khanfar, Maha Habash, Mutasem Omar Taha. J Comput Aided Mol Des 2015
Nour Jamal Jaradat, Mohammad A Khanfar, Maha Habash, Mutasem Omar Taha. J Comput Aided Mol Des 2015
54
Elaborate ligand-based modeling coupled with multiple linear regression and k nearest neighbor QSAR analyses unveiled new nanomolar mTOR inhibitors.
Mohammad A Khanfar, Mutasem O Taha. J Chem Inf Model 2013
Mohammad A Khanfar, Mutasem O Taha. J Chem Inf Model 2013
54
Ligand-based modeling followed by in vitro bioassay yielded new potent glucokinase activators.
Mutasem O Taha, Maha Habash, Ma'mon M Hatmal, Ahmed H Abdelazeem, Amjad Qandil. J Mol Graph Model 2015
Mutasem O Taha, Maha Habash, Ma'mon M Hatmal, Ahmed H Abdelazeem, Amjad Qandil. J Mol Graph Model 2015
54
Discovery of nanomolar phosphoinositide 3-kinase gamma (PI3Kγ) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.
Mutasem O Taha, Mahmoud A Al-Sha'er, Mohammad A Khanfar, Afaf H Al-Nadaf. Eur J Med Chem 2014
Mutasem O Taha, Mahmoud A Al-Sha'er, Mohammad A Khanfar, Afaf H Al-Nadaf. Eur J Med Chem 2014
54
The challenge of selecting protein kinase assays for lead discovery optimization.
Haiching Ma, Sean Deacon, Kurumi Horiuchi. Expert Opin Drug Discov 2008
Haiching Ma, Sean Deacon, Kurumi Horiuchi. Expert Opin Drug Discov 2008
54
Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.
Mutasem O Taha, Yasser Bustanji, Mohamed A S Al-Ghussein, Mohammad Mohammad, Hiba Zalloum, Ihab M Al-Masri, Naji Atallah. J Med Chem 2008
Mutasem O Taha, Yasser Bustanji, Mohamed A S Al-Ghussein, Mohammad Mohammad, Hiba Zalloum, Ihab M Al-Masri, Naji Atallah. J Med Chem 2008
45
Computer-aided discovery of new FGFR-1 inhibitors followed by in vitro validation.
Shada J Alabed, Mohammad Khanfar, Mutasem O Taha. Future Med Chem 2016
Shada J Alabed, Mohammad Khanfar, Mutasem O Taha. Future Med Chem 2016
45
Pharmacophore modeling, quantitative structure-activity relationship analysis, and shape-complemented in silico screening allow access to novel influenza neuraminidase inhibitors.
Areej M Abu Hammad, Mutasem O Taha. J Chem Inf Model 2009
Areej M Abu Hammad, Mutasem O Taha. J Chem Inf Model 2009
36
Scoring noncovalent protein-ligand interactions: a continuous differentiable function tuned to compute binding affinities.
A N Jain. J Comput Aided Mol Des 1996
A N Jain. J Comput Aided Mol Des 1996
36
Discovery of new potent human protein tyrosine phosphatase inhibitors via pharmacophore and QSAR analysis followed by in silico screening.
Mutasem O Taha, Yasser Bustanji, Amal G Al-Bakri, Al-Motassem Yousef, Waleed A Zalloum, Ihab M Al-Masri, Naji Atallah. J Mol Graph Model 2007
Mutasem O Taha, Yasser Bustanji, Amal G Al-Bakri, Al-Motassem Yousef, Waleed A Zalloum, Ihab M Al-Masri, Naji Atallah. J Mol Graph Model 2007
36
High throughput docking for library design and library prioritization.
D J Diller, K M Merz. Proteins 2001
D J Diller, K M Merz. Proteins 2001
36
QSAR studies in the discovery of novel type-II diabetic therapies.
Areej Abuhammad, Mutasem O Taha. Expert Opin Drug Discov 2016
Areej Abuhammad, Mutasem O Taha. Expert Opin Drug Discov 2016
36
Novel variable selection quantitative structure--property relationship approach based on the k-nearest-neighbor principle
Zheng, Tropsha. J Chem Inf Comput Sci 2000
Zheng, Tropsha. J Chem Inf Comput Sci 2000
36
Elaborate ligand-based pharmacophore exploration and QSAR analysis guide the synthesis of novel pyridinium-based potent beta-secretase inhibitory leads.
Afaf Al-Nadaf, Ghassan Abu Sheikha, Mutasem O Taha. Bioorg Med Chem 2010
Afaf Al-Nadaf, Ghassan Abu Sheikha, Mutasem O Taha. Bioorg Med Chem 2010
36
Molecular properties that influence the oral bioavailability of drug candidates.
Daniel F Veber, Stephen R Johnson, Hung-Yuan Cheng, Brian R Smith, Keith W Ward, Kenneth D Kopple. J Med Chem 2002
Daniel F Veber, Stephen R Johnson, Hung-Yuan Cheng, Brian R Smith, Keith W Ward, Kenneth D Kopple. J Med Chem 2002
36
Detailed analysis of grid-based molecular docking: A case study of CDOCKER-A CHARMm-based MD docking algorithm.
Guosheng Wu, Daniel H Robertson, Charles L Brooks, Michal Vieth. J Comput Chem 2003
Guosheng Wu, Daniel H Robertson, Charles L Brooks, Michal Vieth. J Comput Chem 2003
36
Pharmacophore modeling, homology modeling, and in silico screening reveal mammalian target of rapamycin inhibitory activities for sotalol, glyburide, metipranolol, sulfamethizole, glipizide, and pioglitazone.
Mohammad A Khanfar, Majed M AbuKhader, Saja Alqtaishat, Mutasem O Taha. J Mol Graph Model 2013
Mohammad A Khanfar, Majed M AbuKhader, Saja Alqtaishat, Mutasem O Taha. J Mol Graph Model 2013
36
Elaborate ligand-based modeling and subsequent synthetic exploration unveil new nanomolar Ca2+/calmodulin-dependent protein kinase II inhibitory leads.
Rand Shahin, Mutasem O Taha. Bioorg Med Chem 2012
Rand Shahin, Mutasem O Taha. Bioorg Med Chem 2012
36
Elaborate ligand-based modeling reveal new submicromolar Rho kinase inhibitors.
Rand Shahin, Saja Alqtaishat, Mutasem O Taha. J Comput Aided Mol Des 2012
Rand Shahin, Saja Alqtaishat, Mutasem O Taha. J Comput Aided Mol Des 2012
36
Discovery of new renin inhibitory leads via sequential pharmacophore modeling, QSAR analysis, in silico screening and in vitro evaluation.
Afaf H Al-Nadaf, Mutasem O Taha. J Mol Graph Model 2011
Afaf H Al-Nadaf, Mutasem O Taha. J Mol Graph Model 2011
36
Ligand-based modeling of diverse aryalkylamines yields new potent P-glycoprotein inhibitors.
Dana A AlQudah, Malek A Zihlif, Mutasem O Taha. Eur J Med Chem 2016
Dana A AlQudah, Malek A Zihlif, Mutasem O Taha. Eur J Med Chem 2016
36
Computational modeling of the bat HKU4 coronavirus 3CLpro inhibitors as a tool for the development of antivirals against the emerging Middle East respiratory syndrome (MERS) coronavirus.
Areej Abuhammad, Rua'a A Al-Aqtash, Brandon J Anson, Andrew D Mesecar, Mutasem O Taha. J Mol Recognit 2017
Areej Abuhammad, Rua'a A Al-Aqtash, Brandon J Anson, Andrew D Mesecar, Mutasem O Taha. J Mol Recognit 2017
36
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.
C A Lipinski, F Lombardo, B W Dominy, P J Feeney. Adv Drug Deliv Rev 2001
C A Lipinski, F Lombardo, B W Dominy, P J Feeney. Adv Drug Deliv Rev 2001
36
Evaluation of novel Akt1 inhibitors as anticancer agents using virtual co-crystallized pharmacophore generation.
Mahmoud A Al-Sha'er, Iman Mansi, Inas Almazari, Nancy Hakooz. J Mol Graph Model 2015
Mahmoud A Al-Sha'er, Iman Mansi, Inas Almazari, Nancy Hakooz. J Mol Graph Model 2015
40
Ligand-based computational modelling of platelet-derived growth factor beta receptor leading to new angiogenesis inhibitory leads.
Rua'a A Al-Aqtash, Malek A Zihlif, Hana Hammad, Zeyad D Nassar, Jehad Al Meliti, Mutasem O Taha. Comput Biol Chem 2017
Rua'a A Al-Aqtash, Malek A Zihlif, Hana Hammad, Zeyad D Nassar, Jehad Al Meliti, Mutasem O Taha. Comput Biol Chem 2017
44
Discovery of new JNK3 inhibitory chemotypes via QSAR-Guided selection of docking-based pharmacophores and comparison with other structure-based pharmacophore modeling methods.
Ghada Omar Tuffaha, Ma'mon M Hatmal, Mutasem O Taha. J Mol Graph Model 2019
Ghada Omar Tuffaha, Ma'mon M Hatmal, Mutasem O Taha. J Mol Graph Model 2019
36
Discovery of novel Flt3 inhibitory chemotypes through extensive ligand-based and new structure-based pharmacophore modelling methods.
Reem Fawaz Abutayeh, Mutasem O Taha. J Mol Graph Model 2019
Reem Fawaz Abutayeh, Mutasem O Taha. J Mol Graph Model 2019
57
Virtual screening using protein-ligand docking: avoiding artificial enrichment.
Marcel L Verdonk, Valerio Berdini, Michael J Hartshorn, Wijnand T M Mooij, Christopher W Murray, Richard D Taylor, Paul Watson. J Chem Inf Comput Sci 2004
Marcel L Verdonk, Valerio Berdini, Michael J Hartshorn, Wijnand T M Mooij, Christopher W Murray, Richard D Taylor, Paul Watson. J Chem Inf Comput Sci 2004
27
Discovery of new MurF inhibitors via pharmacophore modeling and QSAR analysis followed by in-silico screening.
Mutasem O Taha, Naji Atallah, Amal G Al-Bakri, Catherine Paradis-Bleau, Hiba Zalloum, Khaled S Younis, Roger C Levesque. Bioorg Med Chem 2008
Mutasem O Taha, Naji Atallah, Amal G Al-Bakri, Catherine Paradis-Bleau, Hiba Zalloum, Khaled S Younis, Roger C Levesque. Bioorg Med Chem 2008
27
Ligand-based and structure-based approaches in identifying ideal pharmacophore against c-Jun N-terminal kinase-3.
B V S Suneel Kumar, Rohith Kotla, Revanth Buddiga, Jyoti Roy, Sardar Shamshair Singh, Rambabu Gundla, Muttineni Ravikumar, Jagarlapudi A R P Sarma. J Mol Model 2011
B V S Suneel Kumar, Rohith Kotla, Revanth Buddiga, Jyoti Roy, Sardar Shamshair Singh, Rambabu Gundla, Muttineni Ravikumar, Jagarlapudi A R P Sarma. J Mol Model 2011
30
Combining molecular dynamics simulation and ligand-receptor contacts analysis as a new approach for pharmacophore modeling: beta-secretase 1 and check point kinase 1 as case studies.
Ma'mon M Hatmal, Shadi Jaber, Mutasem O Taha. J Comput Aided Mol Des 2016
Ma'mon M Hatmal, Shadi Jaber, Mutasem O Taha. J Comput Aided Mol Des 2016
27
Enhancing drug discovery through in silico screening: strategies to increase true positives retrieval rates.
J Kirchmair, S Distinto, D Schuster, G Spitzer, T Langer, G Wolber. Curr Med Chem 2008
J Kirchmair, S Distinto, D Schuster, G Spitzer, T Langer, G Wolber. Curr Med Chem 2008
27
Pharmacophore modelling: applications in drug discovery.
Thierry Langer, Rémy D Hoffmann. Expert Opin Drug Discov 2006
Thierry Langer, Rémy D Hoffmann. Expert Opin Drug Discov 2006
27
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.